Product Description
The global therapeutic obstructive sleep apnea device and sleep diagnostic device market sizes are estimated to increase over the forecast period to reach $4.9 billion and $455.1 million, respectively, by 2027.
The majority of the global therapeutic obstructive sleep apnea device market share was controlled by ResMed, Philips Healthcare, and Fisher & Paykel. Similarly, the global sleep diagnostic device market leaders were Philips Healthcare, Natus, and Compumedics.
This global market research spans over 70 countries and includes the global market for obstructive sleep apnea with the positive airway pressure device market and the sleep therapy interface market. In addition, the sleep diagnostic devices market is included with the polysomnography device market and the home respiratory polygraph device market.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2027, and Historical Data to 2017
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Therapeutic Obstructive Sleep Apnea Device Market Insights
The primary driver for therapeutic obstructive sleep apnea devices in many markets is the growing awareness among the general population of sleep apnea symptoms and the benefits of its treatment. COVID-19 did not contribute to an increase in sleep-related conditions but, rather, sleep apnea therapy devices are less complex and easier to assemble than ventilators. In cases of severe COVID-19 where patients require acute care, and also in some home care applications, sleep therapy devices can be used in place of ventilators, contributing to a short-term rise in demand.
Sleep Diagnostic Device Market Insights
The total sleep diagnostic device market is expected to grow steadily throughout the forecast period. Dictating a considerable price point are the polysomnography devices, which are by far the most sophisticated and accurate tests in the market. The ease of use and lower price point of home respiratory polygraphy devices will result in the market’s notable future growth. In certain cases of COVID-19 where patients require acute care, and also in some home care applications, sleep apnea diagnostic devices can be used in place of ventilators, contributing to a short-term rise in demand.
Therapeutic Obstructive Sleep Apnea and Sleep Diagnostic Device MARKET SHARE INSIGHTS
ResMed, Philips Healthcare, and Fisher & Paykel controlled the global therapeutic obstructive sleep apnea device market share. The global sleep diagnostic device market was led by Philips Healthcare, Natus, and Compumedics.
In 2020, ResMed was the leading competitor in the therapeutic obstructive sleep apnea device market, with a notable presence in both the sleep therapy interface and PAP device segments. Philips Healthcare was the leading competitor in the sleep diagnostic device market, with a notable presence in both the polysomnography device and home respiratory polygraphy device segments.
RESEARCH REGIONAL COVERAGE
Throughout this report, iData Research has covered over 70 countries across the globe in great detail. The regions covered are:
- North America (the United States and Canada)
- Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other)
- Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other)
- Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other)
- Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other)
- Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other)
- Africa South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)